BCR-ABL promotes the frequency of mutagenic single-strand annealing DNA repair

Blood

Volumn 114, Issue 9, 2009, Pages 1813-1819

  Fernandes, Margret S ^a,b   Reddy, Mamatha M ^a,b   Gonneville, Jeffrey R ^b   DeRoo, Scott C ^b   Podar, Klaus ^a,b   Griffin, James D ^a,b   Weinstock, David M ^a,b   Sattler, Martin ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; PROTEIN TYROSINE KINASE INHIBITOR; SINGLE STRANDED DNA; PHOSPHATIDYLINOSITOL 3 KINASE; RAS PROTEIN;

ANIMAL CELL; ARTICLE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DISEASE COURSE; DNA REPAIR; GENE FREQUENCY; GENE MUTATION; GENOMIC INSTABILITY; IMMUNOBLOTTING; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; CELL STRAIN K 562; CYTOLOGY; GENETICS; HUMAN; METABOLISM; MOLECULAR GENETICS; MUTAGENESIS; MUTATION; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; STROMA CELL;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; BASE SEQUENCE; DNA REPAIR; DNA, SINGLE-STRANDED; FUSION PROTEINS, BCR-ABL; HUMANS; K562 CELLS; MICE; MOLECULAR SEQUENCE DATA; MUTAGENESIS; MUTATION; OXIDATIVE STRESS; RAS PROTEINS; STROMAL CELLS;

EID: 70349251859     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-07-172148     Document Type: Article

References (44)

1. Walz C, Sattler M. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML). Crit Rev Oncol Hematol. 2006;57:145-164. (Pubitemid 43140744)
2. Banerji L, Sattler M. Targeting mutated tyrosine kinases in the therapy of myeloid leukaemias. Expert Opin Ther Targets. 2004;8:221-239. (Pubitemid 38877673)
3. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408-2417. (Pubitemid 44903745)
4. Sattler M, Verma S, Shrikhande G, et al. The BCR/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells. J Biol Chem. 2000;275:24273-24278. (Pubitemid 30626515)
5. Rodrigues MS, Reddy MM, Sattler M. Cell cycle regulation by oncogenic tyrosine kinases in myeloid neoplasias: from molecular redox mechanisms to health implications. Antioxid Redox Signal. 2008;10:1-36.
6. Koptyra M, Falinski R, Nowicki MO, et al. BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance. Blood. 2006;108:319-327. (Pubitemid 43990645)
7. Nowicki MO, Falinski R, Koptyra M, et al. BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks. Blood. 2004;104:3746-3753. (Pubitemid 39564453)
8. Pierce AJ, Hu P, Han M, Ellis N, Jasin M. Ku DNA end-binding protein modulates homologous repair of double-strand breaks in mammalian cells. Genes Dev. 2001;15:3237-3242. (Pubitemid 34008189)
9. van Gent DC, Hoeijmakers JH, Kanaar R. Chromosomal stability and the DNA double-stranded break connection. Nat Rev Genet. 2001;2:196-206. (Pubitemid 33674018)
10. Lieber MR. The mechanism of human nonhomologous DNA end joining. J Biol Chem. 2008;283:1-5.
11. Dudley DD, Chaudhuri J, Bassing CH, Alt FW. Mechanism and control of V(D)J recombination versus class switch recombination: similarities and differences. Adv Immunol. 2005;86:43-112. (Pubitemid 40215690)
12. Verkaik NS, Esveldt-van Lange RE, van Heemst D, et al. Different types of V(D)J recombination and end-joining defects in DNA double-strand break repair mutant mammalian cells. Eur J Immunol. 2002;32:701-709.
13. Yan CT, Boboila C, Souza EK, et al. IgH class switching and translocations use a robust nonclassical end-joining pathway. Nature. 2007;449:478-482. (Pubitemid 47509538)
14. Johnson RD, Jasin M. Sister chromatid gene conversion is a prominent double-strand break repair pathway in mammalian cells. EMBO J. 2000;19:3398-3407. (Pubitemid 30428217)
15. Stark JM, Pierce AJ, Oh J, Pastink A, Jasin M. Genetic steps of mammalian homologous repair with distinct mutagenic consequences. Mol Cell Biol. 2004;24:9305-9316. (Pubitemid 39391669)
16. Sallmyr A, Tomkinson AE, Rassool FV. Up-regulation of WRN and DNA ligase IIIalpha in chronic myeloid leukemia: consequences for the repair of DNA double strand breaks. Blood. 2008;112:1413-1423.
17. Kim JH, Chu SC, Gramlich JL, et al. Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species. Blood. 2005;105:1717-1723. (Pubitemid 40223695)
18. Sattler M, Mohi MG, Pride YB, et al. Critical role for Gab2 in transformation by BCR/ABL. Cancer Cell. 2002;1:479-492. (Pubitemid 41039128)
19. Richardson C, Moynahan ME, Jasin M. Double-strand break repair by interchromosomal recombination: suppression of chromosomal translocations. Genes Dev. 1998;12:3831-3842. (Pubitemid 29024846)
20. Nakanishi K, Yang YG, Pierce AJ, et al. Human Fanconi anemia monoubiquitination pathway promotes homologous DNA repair. Proc Natl Acad Sci U S A. 2005;102:1110-1115. (Pubitemid 40170734)
21. Walz C, Crowley BJ, Hudon HE, et al. Activated Jak2 with the V617F point mutation promotes G1/S phase transition. J Biol Chem. 2006;281:18177-18183. (Pubitemid 44035617)
22. Elliott B, Richardson C, Jasin M. Chromosomal translocation mechanisms at intronic alu elements in mammalian cells. Mol Cell. 2005;17:885-894. (Pubitemid 40386948)
23. Azam M, Latek RR, Daley GQ. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell. 2003;112:831-843. (Pubitemid 36378885)
24. von Bubnoff N, Barwisch S, Speicher MR, Peschel C, Duyster J. A cell-based screening strategy that predicts mutations in oncogenic tyrosine kinases: implications for clinical resistance in targeted cancer treatment. Cell Cycle. 2005;4:400-406. (Pubitemid 41359724)
25. Jiang X, Zhao Y, Smith C, et al. Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukemia. 2007;21:926-935. (Pubitemid 46672068)
26. Penserga ET, Skorski T. Fusion tyrosine kinases: a result and cause of genomic instability. Oncogene. 2007;26:11-20. (Pubitemid 46067327)
27. Carroll M, Ohno-Jones S, Tamura S, et al. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood. 1997;90:4947-4952. (Pubitemid 28007210)
28. Weisberg E, Boulton C, Kelly LM, et al. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell. 2002;1:433-443. (Pubitemid 41039124)
29. Wernig G, Gonneville JR, Crowley BJ, et al. The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes. Blood. 2008;111:3751-3759.
30. Ma G, Lu D, Wu Y, Liu J, Arlinghaus RB. Bcr phosphorylated on tyrosine 177 binds Grb2. Oncogene. 1997;14:2367-2372. (Pubitemid 27260729)
31. Afar DE, Goga A, McLaughlin J, Witte ON, Sawyers CL. Differential complementation of Bcr-Abl point mutants with c-Myc. Science. 1994;264:424-426. (Pubitemid 24178905)
32. Pendergast AM, Quilliam LA, Cripe LD, et al. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell. 1993;75:175-185. (Pubitemid 23306031)
33. Puil L, Liu J, Gish G, et al. Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway. EMBO J. 1994;13:764-773. (Pubitemid 24057507)
34. Chu S, Li L, Singh H, Bhatia R. BCR-tyrosine 177 plays an essential role in Ras and Akt activation and in human hematopoietic progenitor transformation in chronic myelogenous leukemia. Cancer Res. 2007;67:7045-7053.
35. Canitrot Y, Falinski R, Louat T, et al. p210 BCR/ABL kinase regulates nucleotide excision repair (NER) and resistance to UV radiation. Blood. 2003;102:2632-2637. (Pubitemid 37193605)
36. Stoklosa T, Poplawski T, Koptyra M, et al. BCR/ABL inhibits mismatch repair to protect from apoptosis and induce point mutations. Cancer Res. 2008;68:2576-2580. (Pubitemid 351556254)
37. Bennardo N, Cheng A, Huang N, Stark JM. Alternative-NHEJ is a mechanistically distinct pathway of mammalian chromosome break repair. PLoS Genet. 2008;4:e1000110. (Pubitemid 351914801)
38. Sartori AA, Lukas C, Coates J, et al. Human CtIP promotes DNA end resection. Nature. 2007;450:509-514. (Pubitemid 350190253)
39. Weinstock DM, Jasin M. Alternative pathways for the repair of RAG-induced DNA breaks. Mol Cell Biol. 2006;26:131-139.
40. Deutsch E, Dugray A, AbdulKarim B, et al. BCR-ABL down-regulates the DNA repair protein DNA-PKcs. Blood. 2001;97:2084-2090. (Pubitemid 32239090)
41. Slupianek A, Schmutte C, Tombline G, et al. BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance. Mol Cell. 2001;8:795-806. (Pubitemid 33030213)
42. Dierov J, Dierova R, Carroll M. BCR/ABL translocates to the nucleus and disrupts an ATR-dependent intra-S phase checkpoint. Cancer Cell. 2004;5:275-285. (Pubitemid 38402119)
43. Cramer K, Nieborowska-Skorska M, Koptyra M, et al. BCR/ABL and other kinases from chronic myeloproliferative disorders stimulate single-strand annealing, an unfaithful DNA double-strand break repair. Cancer Res. 2008;68:6884-6888.
44. Raaijmakers MH, Scadden DT. Evolving concepts on the microenvironmental niche for hematopoietic stem cells. Curr Opin Hematol. 2008;15:301-306.